235 related articles for article (PubMed ID: 29485697)
1. Cerebrospinal fluid γδ T cell frequency is age-related: a case-control study of 435 children with inflammatory and non-inflammatory neurological disorders.
Pranzatelli MR; Allison TJ; McGee NR; Tate ED
Clin Exp Immunol; 2018 Jul; 193(1):103-112. PubMed ID: 29485697
[TBL] [Abstract][Full Text] [Related]
2. 6-Mercaptopurine modifies cerebrospinal fluid T cell abnormalities in paediatric opsoclonus-myoclonus as steroid sparer.
Pranzatelli MR; Tate ED; Allison TJ
Clin Exp Immunol; 2017 Nov; 190(2):217-225. PubMed ID: 28710878
[TBL] [Abstract][Full Text] [Related]
3. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
[TBL] [Abstract][Full Text] [Related]
4. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Colliver JA; Ness JM; Ransohoff RM
J Neuroinflammation; 2013 Jan; 10():10. PubMed ID: 23324534
[TBL] [Abstract][Full Text] [Related]
5. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study.
Pranzatelli MR; Allison TJ; Tate ED
Eur J Paediatr Neurol; 2018 Jul; 22(4):586-594. PubMed ID: 29555260
[TBL] [Abstract][Full Text] [Related]
6. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
[TBL] [Abstract][Full Text] [Related]
7. Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Verhulst SJ; Ransohoff RM
Clin Exp Immunol; 2013 Jun; 172(3):427-36. PubMed ID: 23600831
[TBL] [Abstract][Full Text] [Related]
8. Microglial/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges.
Pranzatelli MR; Tate ED; McGee NR
J Neurol Sci; 2017 Oct; 381():285-290. PubMed ID: 28991699
[TBL] [Abstract][Full Text] [Related]
9. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children.
Pranzatelli MR; Tate ED; McGee NR
Pediatr Blood Cancer; 2018 Aug; 65(8):e27097. PubMed ID: 29727049
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders.
Maxeiner HG; Rojewski MT; Schmitt A; Tumani H; Bechter K; Schmitt M
Brain Behav Immun; 2009 Jan; 23(1):134-42. PubMed ID: 18771722
[TBL] [Abstract][Full Text] [Related]
11. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Travelstead AL; Colliver JA
J Clin Immunol; 2010 Jan; 30(1):106-13. PubMed ID: 19838774
[TBL] [Abstract][Full Text] [Related]
12. Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.
Pranzatelli MR; Tate ED; McGee NR
Front Neurol; 2017; 8():468. PubMed ID: 28959231
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED
Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
[TBL] [Abstract][Full Text] [Related]
14. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil.
Pranzatelli MR; Tate ED; Travelstead AL; Baumgardner CA; Gowda NV; Halthore SN; Kerstan P; Kossak BD; Mitchell WG; Taub JW
J Child Neurol; 2009 Mar; 24(3):316-22. PubMed ID: 19258290
[TBL] [Abstract][Full Text] [Related]
15. Enriched CD161high CCR6+ γδ T cells in the cerebrospinal fluid of patients with multiple sclerosis.
Schirmer L; Rothhammer V; Hemmer B; Korn T
JAMA Neurol; 2013 Mar; 70(3):345-51. PubMed ID: 23599932
[TBL] [Abstract][Full Text] [Related]
16. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
[TBL] [Abstract][Full Text] [Related]
17. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
[TBL] [Abstract][Full Text] [Related]
18. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.
Pranzatelli MR; Travelstead AL; Tate ED; Allison TJ; Verhulst SJ
Mov Disord; 2004 Jul; 19(7):770-777. PubMed ID: 15254934
[TBL] [Abstract][Full Text] [Related]
19. Predominance of Vgamma9/Vdelta2 T lymphocytes in the cerebrospinal fluid of children with tuberculous meningitis: reversal after chemotherapy.
Dieli F; Sireci G; Di Sano C; Champagne E; Fourniè JJ; Salerno JI
Mol Med; 1999 May; 5(5):301-12. PubMed ID: 10390546
[TBL] [Abstract][Full Text] [Related]
20. Gamma delta T cell distribution in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis.
Droogan AG; Crockard AD; Hawkins SA; McNeill TA
J Neurol Sci; 1994 Nov; 126(2):172-7. PubMed ID: 7853024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
